Clinical experience of EET therapy for 75 advanced cancer patients

Anticancer Research

Volumn 18, Issue 5 D, 1998, Pages 3941-3949

  Kato, Mikio ^a   Shinohara, Hisashi ^b   Goto, Shigenori ^c   Takagi, Koichi ^d   Soma, Gen Ichiro ^d,e  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b National Okura Hospital   (Japan)

^c Kitatama Hospital   (Japan)

^d TAKANO HOSPITAL   (Japan)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer; Danger theory; Endogenous induction; Exogenous and endogenous TNF therapy; TNF

Indexed keywords

GAMMA INTERFERON; PICIBANIL; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CHILL; COLON CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DYSPNEA; FEMALE; FEVER; GYNECOLOGIC CANCER; HELPER CELL; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; RHABDOMYOSARCOMA; THROMBOCYTOPENIA; URINARY TRACT CANCER; UTERINE CERVIX CANCER; VOMITING;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; MALE; MIDDLE AGED; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031797693     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Boon T and van der Bruggen P: Human tumor antigens recognized by T lymphocytes. J Exp Med 183: 725-729, 1996.
2. Fearon DT and Locksley RM: The instructive role of innate immunity in the acquired immune response. Science 272: 50-53, 1996.
3. Medzhitov R, Preston-Hurlburt P and Janeway CA Jr: A human homologue of the Drosophilla Toll protein signals activation of adaptive immunity. Nature 388: 394-397, 1997.
4. Matzinger P: Tolerance, danger, and the extended family. Ann Rev Immunol 12: 991-1045, 1994.
5. Fuchs EJ, Matzinger P: Is cancer dangerous to the immune system? Semin Immunol 8: 271-280, 1996.
6. Satoh M, Inagawa H, Shimada Y, Soma G-I, Oshima H and Mizuno D-I: Endogenous production of tumor necrosis factor in normal mice and human cancer patients by interferons and other cytokines combined with biological response modifiers of bacterial origin. J Biol Resp Mod 6: 512-524, 1987.
7. Kato M, Kakehi R, Soma G-I and Mizuno D-I: Anti-tumor therapy by induction of endogenous tumor necrosis factor. Lancet ii: 270, 1985.
8. Gatanaga T, Noguchi K, Tanabe Y, Inagawa H, Soma G-I and Mizuno D-I: Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-a in vivo. J Biol Resp Mod 8: 278-286, 1989.
9. Havell EA, Fiers W and North RJ: The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 167: 1067-1085, 1988.
10. North RJ and Havell EA: The antitumor function of tumor necrosis factor (TNF). II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma. J Exp Med 167: 1086-1099, 1988.
11. Ridge JP, Fuchs EJ and Matzinger P: Neonatal tolerance revisited : Turning on newborn T cells with dendritic cells. Science 277: 1723-1726, 1997.
12. Cella M, Engering A, Pinet V, Pieters J and Lanzavecchia A: Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388: 782-787, 1997.
13. Wang B, Kondo S, Shivji GM, Fujisawa H, Mak TW and Sauder DN: Tumor necrosis factor receptor II (p75) signalling is required for the migration of Langerhans' cells. Immunology 88: 284-288, 1996.
14. Srivastava PK: Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Semin Immunol 8: 295-302, 1996.
15. Huang AYC, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM and Jaffee EM: The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derived from an endogenous retroviral gene product. Proc Natl Acad Sci USA 93: 9730-9735, 1996.
16. Tamura Y, Peng P, Liu K, Daou M and Srivastava PK: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278: 117-120, 1997.
17. Shie Y, Tamaoki T, Tanaka M, Kojima R and Kawamura A: Induction of heat shock protein by OK-432. Jpn J Transpl 32 (Proceed the 33 JST Annual Meet): 265, 1997.
18. Wei Y, Zhao X, Kariya Y, Fukata H, Teshigawara K and Uchida A: Induction of autologous tumor killing by heat treatment of fresh human tumor cells: Involvement of g d T cells and heat shock protein 70. Cancer Res 56: 1104-1110, 1996.
19. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM and Ohashi PS: Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. J Exp Med 186: 645-653, 1997.
20. Nauts HC, Fowler GA and Bogatko FH: A review of the influence of bacterial infection and bacterial products (Coley's toxins) on malignant tumors in man. Acta Medica Scand 45 (suppl 276): 1-103, 1953.
21. Yang R, Sanghvi NT, Rescorla FJ, Kopecky KK and Grosfeld JL: Liver cancer ablation with extracorporeal high-intensity focused ultrasound. Eur Urol 23(suppl 1): 17-22, 1993.
22. Lienard D, Ewalenko P, Delmotte J, Renard N and Lejeune FJ: High dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60, 1992.
23. Eggermont AMM, Manusama ER and ten Hagen LM: Regional application of TNF a in the treatment of cancer: A preclinical-clinical interactive program. J Inflammation 47: 104-113, 1996.
24. Seino K, Kayagaki N, Okumura K and Yagita H: Antitumor effect of locally produced CD95 ligand. Nature Med 3: 165-170, 1997.